Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients.

Author: Shan-Shan SUO ¹ ; Chen-Ying LI ¹ ; Yi ZHANG ¹ ; Jing-Han WANG ¹ ; Yin-Jun LOU ¹ ; Wen-Juan YU ¹ ; Jie JIN ¹
Author Information

1. Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Publication Type:Journal Article
Keywords: Acute lymphoblastic leukemia; Diabetes mellitus; Clinical characteristics
MeSH: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents/adverse effects*; Diabetes Mellitus/chemically induced*; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality*; Young Adult
From: Journal of Zhejiang University. Science. B 2020;21(9):740-744
CountryChina
Language:English
Abstract: Acute lymphocytic leukemia (ALL) is one of the most common malignancies, especially in young people. Combination chemotherapy for ALL typically includes corticosteroids (Kantarjian et al., 2000). Hyperglycemia is a well-recognized complication of corticosteroids, and chemotherapy-induced diabetes (CID) is not uncommon (27.5%-37.0%) during the treatment of ALL (Hsu et al., 2002; Weiser et al., 2004; Alves et al., 2007). Besides the effect of corticosteroids, potential factors triggering hyperglycemia in ALL also include direct infiltration of the pancreas by leukemia cells and β cell dysfunction induced by chemotherapeutic agents such as L-asparagine (Mohn et al., 2004).